The development of high-throughput technologies and bioinformatics have identified candidate biomarkers that play important roles in NPC development, such as Serine Peptidase Inhibitor Kazal Type 6 (SPINK6), HOP Homeobox (HOPX) and Shisa Family Member 3 (SHISA3) [6–8], and transcription factors (TFs) that may offer therapeutic targets. This evidence concerns the gene SHISA3 and nasopharyngeal carcinoma.